Agenda Topics- Fragment Based Drug Discovery
- Models For Success
- New Lead Identification
- Open Innovation
Sponsorship and Exhibition OpportunitiesExhibition Team, exhibitors@selectbio.com +44 (0) 1206 501654
|
Distinguished FacultyRoland Wolkowicz, Associate Professor, San Diego State University Christian Ottmann, Associate Professor, Technische Universiteit Eindhoven Jessica Vamathevan, Centre for Therapeutic Target Validation (CTTV) Operations Director, GlaxoSmithKline Chas Bountra, Chief Scientist, University of Oxford Annika Jenmalm Jensen, Consortium Director, CBCS Director, LCBKI, Karolinska Institutet Justin Bryans, Director of Drug Discovery, Medical Research Council Technology Timothy Hemesath, Director, Biotherapeutics Site Biology and Operations Lead, Centers for Therapeutic Innovation (CTI), Pfizer James Chen, Executive Director, HTBC, Stanford University Marc Nazare, Group Leader Medicinal Chemistry, Leibniz-Institut für Molekulare Pharmakologie FMP, Berlin Jan Steyaert, Group Leader/Director, Vrije Universiteit Brussels Olivia Rossanese, Head of Biology and Reader, CR UK Cancer Therapeutics Unit, Institute of Cancer Research Stuart McElroy, Head of Biology, European Screening Centre Newhouse , University of Dundee Martin Drysdale, Head of Drug Discovery Programme, The Beatson Institute for Cancer Research Philip Jones, Head of Drug Discovery, Institute for Applied Cancer Science. MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center Paul Wyatt, Head of the Drug Discovery Unit, University of Dundee Richard Houghten, President, Torrey Pines Institute for Molecular Studies David Smith, Principal Scientist, AstraZeneca R&D Mikael Elofsson, Professor, University of Umeå Edward Tate, Professor of Chemical Biology, Imperial College London
|